Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.

Vittorio Gebbia, Verderame, Evaristo Maiello, Colucci, Michele Caruso, Di Cristina, Di Maggio, Nicolò Borsellino, Francesco Giuliani, Roberto Bordonaro, Paolo Tralongo, Francesco Ferraù

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support. Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity. Results: Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1–7 months), and median overall survival (OS) was 6.7 months (range 2–9 months). A stabilization of performance status (PS) and a subjective improvement of cancer-related symptoms were recorded in 27 patients. Conclusions: Data presented in this paper support the use of FOLFOX4 regimen in the second-line treatment of adenocarcinoma of the pancreas patients. The use of SLCT, however, should be carefully proposed to patients with good PS or those who had a good response to first-line therapy.
Original languageEnglish
Pages (from-to)124-127
Number of pages4
JournalAnnals of Oncology
Volume18 suppl. 6
Publication statusPublished - 2007

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. / Gebbia, Vittorio; Verderame; Maiello, Evaristo; Colucci; Caruso, Michele; Di Cristina; Di Maggio; Borsellino, Nicolò; Giuliani, Francesco; Bordonaro, Roberto; Tralongo, Paolo; Ferraù, Francesco.

In: Annals of Oncology, Vol. 18 suppl. 6, 2007, p. 124-127.

Research output: Contribution to journalArticle

Gebbia, V, Verderame, Maiello, E, Colucci, Caruso, M, Di Cristina, Di Maggio, Borsellino, N, Giuliani, F, Bordonaro, R, Tralongo, P & Ferraù, F 2007, 'Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.', Annals of Oncology, vol. 18 suppl. 6, pp. 124-127.
Gebbia, Vittorio ; Verderame ; Maiello, Evaristo ; Colucci ; Caruso, Michele ; Di Cristina ; Di Maggio ; Borsellino, Nicolò ; Giuliani, Francesco ; Bordonaro, Roberto ; Tralongo, Paolo ; Ferraù, Francesco. / Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. In: Annals of Oncology. 2007 ; Vol. 18 suppl. 6. pp. 124-127.
@article{efa205cc944141c98107ca629193eb82,
title = "Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.",
abstract = "Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support. Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity. Results: Six partial responses (14{\%}) and 16 stabilizations (38{\%}) were recorded for a tumor growth control rate of 57{\%}. The median time to progression (TtP) was 4 months (range 1–7 months), and median overall survival (OS) was 6.7 months (range 2–9 months). A stabilization of performance status (PS) and a subjective improvement of cancer-related symptoms were recorded in 27 patients. Conclusions: Data presented in this paper support the use of FOLFOX4 regimen in the second-line treatment of adenocarcinoma of the pancreas patients. The use of SLCT, however, should be carefully proposed to patients with good PS or those who had a good response to first-line therapy.",
author = "Vittorio Gebbia and Verderame and Evaristo Maiello and Colucci and Michele Caruso and {Di Cristina} and {Di Maggio} and Nicol{\`o} Borsellino and Francesco Giuliani and Roberto Bordonaro and Paolo Tralongo and Francesco Ferra{\`u}",
year = "2007",
language = "English",
volume = "18 suppl. 6",
pages = "124--127",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.

AU - Gebbia, Vittorio

AU - Verderame, null

AU - Maiello, Evaristo

AU - Colucci, null

AU - Caruso, Michele

AU - Di Cristina, null

AU - Di Maggio, null

AU - Borsellino, Nicolò

AU - Giuliani, Francesco

AU - Bordonaro, Roberto

AU - Tralongo, Paolo

AU - Ferraù, Francesco

PY - 2007

Y1 - 2007

N2 - Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support. Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity. Results: Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1–7 months), and median overall survival (OS) was 6.7 months (range 2–9 months). A stabilization of performance status (PS) and a subjective improvement of cancer-related symptoms were recorded in 27 patients. Conclusions: Data presented in this paper support the use of FOLFOX4 regimen in the second-line treatment of adenocarcinoma of the pancreas patients. The use of SLCT, however, should be carefully proposed to patients with good PS or those who had a good response to first-line therapy.

AB - Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support. Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity. Results: Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1–7 months), and median overall survival (OS) was 6.7 months (range 2–9 months). A stabilization of performance status (PS) and a subjective improvement of cancer-related symptoms were recorded in 27 patients. Conclusions: Data presented in this paper support the use of FOLFOX4 regimen in the second-line treatment of adenocarcinoma of the pancreas patients. The use of SLCT, however, should be carefully proposed to patients with good PS or those who had a good response to first-line therapy.

UR - http://hdl.handle.net/10447/17598

UR - file:///C:/Users/Utente/Desktop/Second%20line%20chemotherapy%20...%202007.pdf

M3 - Article

VL - 18 suppl. 6

SP - 124

EP - 127

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -